NCT03843359View on ClinicalTrials.gov

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

April 5, 2024

Study Completion Date

March 31, 2025

Conditions
Neoplasms
Interventions
DRUG

GSK3745417

GSK3745417 will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered.

Trial Locations (13)

3000

GSK Investigational Site, Melbourne

28040

GSK Investigational Site, Madrid

28050

GSK Investigational Site, Madrid

33076

GSK Investigational Site, Bordeaux

77030

GSK Investigational Site, Houston

94805

GSK Investigational Site, Villejuif

M5G 1Z9

GSK Investigational Site, Toronto

104-0045

GSK Investigational Site, Tokyo

135-8550

GSK Investigational Site, Tokyo

1066 CX

GSK Investigational Site, Amsterdam

1081 HV

GSK Investigational Site, Amsterdam

03080

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03843359 - A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter